News

Thanks to a deal reached by NHS England, a targeted new medicine for a rare and severe form of lung cancer will be accessible to qualified patients within weeks. Mobocertinib, the only precision medicine accessible to patients with a...

Patrick McGrath brings more than 20 years of cold chain industry experience to the role Peli BioThermal, the life science industry’s cold chain partner from discovery to distribution, announces Patrick McGrath as its new Director of Sales, Americas. McGrath will...

Pfizer and BioNTech announced Tuesday that they have filed an application to the US Food and Drug Administration for urgent use permission of an extra booster dose of their COVID-19 vaccine for adults 65 or older who have already...

Biogen Inc. announced that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM. Effective as of January 1, 2023, Eisai will receive a tiered royalty based on net sales...

OcyonBio announces manufacturing and operations agreement to develop biosimilar drug product facilities for Biosimilar Solutions, Inc. OcyonBio is creating an advanced therapy contract development, manufacturing organization (CDMO) that provides pre-clinical through commercial manufacturing including process development, plasmid DNA, viral...

A German independent research institute, BioMed X, announces  the start of its new research project ‘Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging’ (TDA) in collaboration with Merck KGaA, Darmstadt, Germany. The main objective of the research group TDA...

The FDA approved the AstraZeneca and Merck medications for a select subset of individuals with severe early-stage breast cancer, after chemotherapy before or after surgery. The patient's tumour must have BRCA mutations in the germline and be HER2-negative. According to...